AnaptysBio Inc

NASDAQ:ANAB   3:59:59 PM EDT
24.55
-0.34 (-1.37%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)671.89M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$31.71 Million
Adjusted EPS-$0.01
See more estimates
10-Day MA$24.30
50-Day MA$23.77
200-Day MA$23.43
See more pivots

AnaptysBio Inc Stock, NASDAQ:ANAB

10770 Wateridge Circle, Suite 210, San Diego, California 92121-5801
United States of America
Phone: +1.858.362.6295
Number of Employees: 94

Description

AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.